Approved Date Route External Links
2016-07-07 Oral Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications & Usage Section 1.1 Major Depressive Disorder Duloxetine Delayed-Release Capsules Are Indicated For The Treatment Of Major Depressive Disorder (mdd). The Efficacy Of Duloxetine Delayed-Release Capsules Was Established In Four Short-Term And One Maintenance Trial In Adults [see Clinical Studies (14.1)]. A Major Depressive Episode (dsm-Iv) Implies A Prominent And Relatively Persistent (nearly Every Day For At Least 2 Weeks) Depressed Or Dysphoric Mood That Usually Interferes With Daily Functioning, And Includes At Least 5 Of The Following 9 Symptoms: Depressed Mood, Loss Of Interest In Usual Activities, Significant Change In Weight And/or Appetite, Insomnia Or Hypersomnia, Psychomotor Agitation Or Retardation, Increased Fatigue, Feelings Of Guilt Or Worthlessness, Slowed Thinking Or Impaired Concentration, Or A Suicide Attempt Or Suicidal Ideation. 1.2 Generalized Anxiety Disorder Duloxetine Delayed-Release Capsules Are Indicated For The Treatment Of Generalized Anxiety Disorder (gad). The Efficacy Of Duloxetine Delayed-Release Capsules Was Established In Three Short-Term Trials And One Maintenance Trial In Adults [see Clinical Studies (14.2)]. Generalized Anxiety Disorder Is Defined By The Dsm-Iv As Excessive Anxiety And Worry, Present More Days Than Not, For At Least 6 Months. The Excessive Anxiety And Worry Must Be Difficult To Control And Must Cause Significant Distress Or Impairment In Normal Functioning. It Must Be Associated With At Least 3 Of The Following 6 Symptoms: Restlessness Or Feeling Keyed Up Or On Edge, Being Easily Fatigued, Difficulty Concentrating Or Mind Going Blank, Irritability, Muscle Tension, And/or Sleep Disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Duloxetine Delayed-Release Capsules Are Indicated For The Management Of Neuropathic Pain (dpnp) Associated With Diabetic Peripheral Neuropathy [see Clinical Studies (14.3)]. 1.5 Chronic Musculoskeletal Pain Duloxetine Delayed-Release Capsules Are Indicated For The Management Of Chronic Musculoskeletal Pain. This Has Been Established In Studies In Patients With Chronic Low Back Pain (clbp) And Chronic Pain Due To Osteoarthritis [see Clinical Studies (14.5)].

All Formulated Excipients (9 Total)

Name Structure Kind Function Status
1. Titanium Dioxide TITANIUM DIOXIDE Unresolved DYE-Dye
2. Talc TALC Unresolved DYE-Dye GRAS-Generally recognized as safe.
3. Sucrose SUCROSE Molecular NUTRS-Nutritive Sweetener GRAS-Generally recognized as safe.
4. Shellac SHELLAC Unresolved
5. Propylene Glycol PROPYLENE GLYCOL Molecular MISC-Miscellaneous FS-Substances permitted as optional ingredient in a standardized food.
6. Potassium Hydroxide POTASSIUM HYDROXIDE Unresolved B&N-Buffer & neutralizing agent , MISC-Miscellaneous FS-Substances permitted as optional ingredient in a standardized food.
7. Polysorbate 80 POLYSORBATE 80 Unresolved AF-Antifoaming (or defoaming) agent , EMUL-Emulsifier , MISC-Miscellaneous , SDA-Solubilizing & dispersing agent REG-Food additives for which a petition has been filed and a regulation issued.
8. Hypromelloses HYPROMELLOSES Unresolved
9. Ferrosoferric Oxide FERROSOFERRIC OXIDE Unresolved

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Duloxetine Hydrochloride DULOXETINE HYDROCHLORIDE ZINC1536779

Comments